A recent review published in JAMA Psychiatry suggests that withdrawal symptoms from antidepressants are not significant. However, critics say the review fails to address the real risks faced by long-term users and relies too heavily on short-term, industry-funded studies.
Experts are concerned that this review could mislead healthcare providers and patients. It echoes outdated views from earlier medical guidelines that labeled withdrawal symptoms as “mild and brief”—a stance based on studies where people only took antidepressants for 8 to 12 weeks. But for millions of people who have used these medications for years, the experience of stopping them can be far more severe.
Short-Term Studies Misrepresent Long-Term Realities
Past guidelines from the UK’s National Institute for Health and Care Excellence (NICE) were based on short clinical trials sponsored by drug manufacturers. These trials didn’t capture the long-term effects of stopping antidepressants. As a result, many doctors did not take patients’ withdrawal complaints seriously when symptoms didn’t match what the guidelines had predicted.
New research is now highlighting the true risks. A study surveying NHS patients found that those who used antidepressants for more than two years were:
- 10 times more likely to experience withdrawal symptoms,
- 5 times more likely to experience severe symptoms,
- 18 times more likely to report symptoms lasting longer than those who used them for six months or less.
By contrast, short-term users generally had fewer issues. Three out of four reported either no symptoms or mild ones lasting less than four weeks. Only one in four had trouble stopping the medication.
Among long-term users, the picture was different:
- Two-thirds had moderate to severe withdrawal effects,
- One-quarter experienced severe symptoms,
- Nearly one-third had symptoms that lasted more than three months,
- Four out of five were unable to stop despite trying.
In England alone, about 2 million people have been on antidepressants for over five years. In the U.S., that number is over 25 million. Their experiences are not represented in eight-week studies.
Flawed Review Repeats Past Mistakes
The new JAMA Psychiatry review, authored by academics—many of whom have ties to drug companies—draws its conclusions from eleven short-term studies. Most involved participants who had used antidepressants for just 8 to 12 weeks. Only one study lasted six months.
The review found slightly more withdrawal symptoms in those who stopped the drugs, but deemed them not “clinically significant.” It also suggested the symptoms could result from the nocebo effect, where negative expectations make people feel worse.
Experts argue these conclusions are misleading for several reasons:
Too Few Long-Term Studies: The review didn’t include enough long-term trials to understand how extended use affects withdrawal.
Faulty Comparisons: It assumed that because people stopping placebos also report symptoms, the withdrawal effects from antidepressants are minimal. However, the symptoms from stopping real medications are often far worse.
Ignored Evidence: Some rigorous industry-run studies that did find high withdrawal rates—such as one U.S. trial showing 60% of people experienced symptoms after stopping antidepressants—were left out.
Real-Life Consequences Overlooked
Withdrawal symptoms aren’t just uncomfortable—they can be disabling. Some people need emergency care when trying to stop their medications. Symptoms like dizziness, nausea, and brain “zaps” can severely affect daily life. These intense reactions are not typically seen with placebos.
Critics also disagree with the review’s claim that depressive symptoms after stopping antidepressants reflect a relapse rather than withdrawal. This view relies on data from just five studies and uses weak methods—like unprompted self-reports from participants—rather than formal assessments.
Why This Matters Now
The publication of this review comes at a time when governments and health authorities are finally starting to recognize antidepressant withdrawal as a public health issue. Critics fear this new review could set back progress by downplaying a serious problem and delaying needed changes to clinical care.
Short-term studies, they argue, are like crash-testing a car at 5km/h while ignoring how it performs at highway speeds. They fail to reflect the reality faced by millions of long-term users trying to safely come off their medications.
Conclusion
While the review claims that withdrawal symptoms from antidepressants are not significant, it relies heavily on outdated and short-term research. For long-term users, the risk of severe and long-lasting withdrawal effects is real—and still largely under-recognized.
Uncritical acceptance of this review could undo years of effort to bring attention to the issue and delay crucial support for millions struggling to stop antidepressants safely.
READ MORE
